First-Line Antifibrotic Choice in Idiopathic Pulmonary Fibrosis
A retired surveyor newly diagnosed with IPF has three real antifibrotic options for the first time — the disagreement isn't whether to treat, but which of a newly approved drug and two long-established ones actually fits him.
R.D., a 71-year-old man, spent forty years surveying county roads before retiring, and has spent most of the time since restoring a wooden sailboat his father built, sanding and varnishing on the dock most afternoons regardless of the weather. Six months ago a persistent dry cough and creeping breathlessness sent him to his internist, and a high-resolution CT read as definite usual interstitial pneumonia — confirmed by multidisciplinary review, no biopsy needed given the classic pattern, no connective-tissue serology positive. His FVC came back at 68% predicted, already a meaningful drop for a man who was rowing three miles a week eighteen months ago, and his DLCO at 52% told the same story from a different angle. He takes nothing regularly besides an occasional ibuprofen for a bad shoulder — no daily medication at all, at seventy-one — and his transaminases and kidney function are both normal, which is less a reassurance than a starting line: two of the three drugs in front of him are judged partly by what those numbers do over the following year.
Idiopathic pulmonary fibrosis now has three real antifibrotic options, not two. Pirfenidone (ASCEND) and nintedanib (INPULSIS) have anchored practice for more than a decade; nerandomilast, a phosphodiesterase-4B inhibitor approved for IPF in October 2025, is the first genuinely new mechanism in that stretch. In the FIBRONEER-IPF trial's 1,177 patients, nerandomilast met its primary endpoint, slowing FVC decline against placebo over 52 weeks. Its composite key secondary endpoint was not met, and its own mortality figure — a hazard ratio of 0.66 at the higher dose, with a confidence interval crossing 1 — is a numerical trend, not a demonstrated survival benefit. R.D. also sits outside the trial's center of gravity in a way that matters more than the headline does: better than three quarters of FIBRONEER's participants were already taking pirfenidone or nintedanib, so what the trial mostly measured was nerandomilast added on top of an established drug rather than standing in place of one. He is treatment-naive, which is the version of the question the trial answers least directly. None of the three has been compared head-to-head against another. What the team actually has to weigh is not a ranked list but three different kinds of uncertainty — a newer mechanism with a cleaner early safety signal, against two familiar drugs whose failure modes are already well mapped, against R.D.'s own life: hours outdoors on that dock most days, in direct sun, are exactly the setting pirfenidone's photosensitivity warning was written for.
Choosing the first drug
Start nerandomilast. FIBRONEER-IPF enrolled 1,177 patients and found a real, statistically significant slowing in FVC decline against placebo, and Oldham and colleagues' pooled analysis of the two FIBRONEER trials found a mortality hazard ratio of 0.57 at the 18mg dose — a real signal, though I'll grant it borrows strength from the progressive-pulmonary-fibrosis trial, where the mortality result was much cleaner than in IPF alone. What actually matters for R.D. today is the adverse-effect profile behind that number: diarrhea, nausea, fatigue — not the transaminitis nintedanib requires monthly labs to catch, not the phototoxicity that would put a man who lives on his dock at real risk with pirfenidone.
You're right that FIBRONEER's tolerability data is the strongest argument for nerandomilast, and I won't argue the number away. And that is exactly my objection: in FIBRONEER-IPF by itself the hazard ratio for death was 0.66, confidence interval running past 1. The pooled figure gets its significance from patients who don't have R.D.'s disease. A trend from one still-young trial program is not the same claim as a decade of open-label extension and registry follow-up on pirfenidone and nintedanib — real data on what actually happens to a patient's liver, his cardiovascular risk, his bleeding risk, over years rather than the roughly one year FIBRONEER's participants have been followed. An incurable disease with a median survival measured in years is exactly the setting where being the newest drug in a class is a caution, not just a credential.
Between the two established drugs specifically, though, this decision is closer than it sounds, and it's R.D.'s own life that settles it. Pirfenidone's photosensitivity reaction is common, dose-related, and would either curtail the exact activity that has kept him engaged and moving since his diagnosis, or go unheeded and produce a real burn. Nintedanib carries no comparable phototoxicity warning. That doesn't resolve whether nerandomilast is the better long-run choice — it resolves which of the two proven drugs would have been wrong for him, and narrows this to a genuine two-way decision rather than three roughly equal options.
Agreed: start nintedanib 150mg twice daily, with liver function testing at two and four weeks then monthly; nerandomilast held as the next step if tolerability becomes limiting or if his decline continues despite treatment.
Not agreed: whether nerandomilast should become the default first choice for a treatment-naive patient like R.D. once a full year of real-world safety data accumulates — the ILD specialist expects that shift within the year; the Pulmonary and Critical Care Physician wants to watch an actual mature cohort first, not just a second trial readout.